Interleukin 9 mediates T follicular helper cell activation to promote antibody responses
Antigen-specific humoral responses are orchestrated through complex interactions among immune cells in lymphoid tissues, including the collaboration between B cells and T follicular helper (Tfh) cells. Accumulating evidence indicates a crucial role for interleukin-9 (IL-9) in the formation of germinal centers (GCs), enhancing the generation of class-switched high-affinity antibodies. However, the exact function of IL-9 in Tfh cell regulation remains unclear. In this study, we examined the humoral immune responses of CD4<sup>Cre/+</sup>Il9ra<sup>fl/fl</sup> mice, which lack an IL-9-specific receptor in Tfh cells. Upon intraperitoneal immunization with sheep red blood cells (SRBCs), CD4<sup>Cre/+</sup>Il9ra<sup>fl/fl</sup> mice displayed diminished levels of SRBC-specific IgG antibodies in their sera, along with reduced levels of GC B cells and plasma cells. Notably, Il9ra-deficient Tfh cells in the spleen exhibited decreased expression of their signature molecules such as B-cell lymphoma 6, C-X-C chemokine receptor 5, IL-4, and IL-21 compared to control mice. In models of allergic asthma induced by house dust mite (HDM) inhalation, CD4<sup>Cre/+</sup>Il9ra<sup>fl/fl</sup> mice failed to elevate serum levels of HDM-specific IgE and IgG. This was accompanied by reductions in Tfh cells, GC B cells, and plasma cells in mediastinal lymph nodes. Furthermore, group 2 innate lymphoid cells (ILC2s) were identified as producers of IL-9 under immunizing conditions, possibly induced by leukotrienes released by activated IgD<sup>+</sup> B cells around the T-B border. These observations may indicate the critical role of IL-9 receptor signaling in the activation of Tfh cells, with ILC2s potentially capable of supplying IL-9 in organized lymphoid tissues.
Authors
- Takeshi Ohyu
- Ippei Ikegami (ORCID: https://orcid.org/0000-0001-5173-8249)
- Masahiro Miyajima
- Masahiro Yanagi (ORCID: https://orcid.org/0000-0002-1851-4160)
- Ryuta Kamekura (ORCID: https://orcid.org/0000-0002-9921-947X)
- Kenichi Takano (ORCID: https://orcid.org/0000-0001-8706-6384)
- Masanobu Tanemoto (ORCID: https://orcid.org/0000-0002-1923-3598)
- Shingo Ichimiya (ORCID: https://orcid.org/0000-0003-2874-774X)
- Taiki Sato (ORCID: https://orcid.org/0000-0002-6437-8630)
- Shiori Kamiya (ORCID: https://orcid.org/0000-0002-5371-4395)
- Atsushi Watanabe
- Akinori Sato (ORCID: https://orcid.org/0000-0001-9011-1756)
- Yuka Kamada (ORCID: https://orcid.org/0000-0002-2783-182X)
- Shotaro Shirato
- T Sugaya
- Kohei Kikuchi
- Takehito Nakata
Institutions
- Sapporo Medical University (JP)
- Hokkaido Bunkyo University (JP)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-09-30
- DOI
- https://doi.org/10.3389/fimmu.2024.1441407
- Citations
- 6
- Primary Topic
- IL-33, ST2, and ILC Pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.44
Funders
- GlaxoSmithKline Japan
- Japan Society for the Promotion of Science